About Kenneth Horne
Ken Horne is managing partner of AN Venture Partners, which co-led Typewriter's Series A, and he chairs Typewriter's board. He also chairs Pahr Therapeutics, Kan Therapeutics, Capacity Bio, En Biotherapeutics and Ando Therapeutics, and he co-founded or led Aline Aesthetics, Symic Bio and Teon Therapeutics.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Kenneth Horne in the role, so the role may have started earlier or lasted longer.
Typewriter Therapeutics, Inc. Current
Board Chair
2026 – Present · Cambridge, MA
Typewriter Therapeutics develops all-RNA medicines that insert a full working gene at a natural safe harbor site in the genome, starting with in vivo CAR-T.
Capacity Bio, Inc. Current
Chief Executive Officer and director
Board Chair
2023 – Present · Palo Alto, CA
AP
AN Venture Partners Current
Managing Partner
KT
Kan Therapeutics Current
Board Chair
EB
En Biotherapeutics Current
Board Chair
AT
Ando Therapeutics Current
Board Chair
RV
RDiscovery (Remiges Ventures)
Chair
AA
Aline Aesthetics
SB
Symic Bio
TT
Teon Therapeutics
TN
Tortugas Neuroscience
Board member
Education
- BS, Mechanical Engineering, Stanford University
- MS, Mechanical Engineering, Stanford University
Key Colleagues at Startups
The people Kenneth Horne works with at each company, as listed on that company's latest Form D.
Typewriter Therapeutics, Inc. · Form D, Sep 21, 2026
LT
Laura Tadvalkar
Director
MS
Matthew Stanton
Chief Executive Officer and Board Director
MD
Mikael Dolsten
Independent Board Director
Imbria Pharmaceuticals, Inc. · Form D/A, Dec 16, 2025
PC
Pavan Cheruvu
Director
CD
Charles Dunn
Director
AS
Alvin Shih
Executive officer and director
LR
Luse Rebecca
Director
KJ
Komal Joshi
Secretary
AL
Andrew Levin
Director
Zina Affas Besse
Director
Pahr Therapeutics, Inc. · Form D, Jul 18, 2025
AU
Atsushi Usami
Director
AL
Andrew Levin
Director
NB
Neil Buckley
President and director
AC
Amanda Creedon
Executive officer
Capacity Bio, Inc. · Form D, Jan 18, 2023
TI
Taro Inaba
Director
DM
Dylan Morris
Director
AW
Amy Wang
Executive officer and director
CG
Cristina Ghenoiu
Director
Kenneth Horne in the News
Sources
- SECTypewriter Therapeutics, Inc. Form D, filed Sep 21, 2026
- SECImbria Pharmaceuticals, Inc. Form D/A, filed Dec 16, 2025
- SECPahr Therapeutics, Inc. Form D, filed Jul 18, 2025
- SECCapacity Bio, Inc. Form D, filed Jan 18, 2023
- Officialtypewritertx.com, Ken Horne bio
- Officialan.vc, team page (Managing Partner)
- Officialan.vc, Series A post (continues as Typewriter board chair, 2026-09-02)
- Officialtypewritertx.com, Series A release naming him board chair (2026-09-02)